ZA202402786B - Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis - Google Patents

Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis

Info

Publication number
ZA202402786B
ZA202402786B ZA2024/02786A ZA202402786A ZA202402786B ZA 202402786 B ZA202402786 B ZA 202402786B ZA 2024/02786 A ZA2024/02786 A ZA 2024/02786A ZA 202402786 A ZA202402786 A ZA 202402786A ZA 202402786 B ZA202402786 B ZA 202402786B
Authority
ZA
South Africa
Prior art keywords
coated
oral formulation
prophylaxis
treatment
intestinal fibrosis
Prior art date
Application number
ZA2024/02786A
Other languages
English (en)
Inventor
Wilhelm Rudolf
Tewes Bernhard
GREINWALD Roland
Original Assignee
Dr Falk Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma Gmbh filed Critical Dr Falk Pharma Gmbh
Publication of ZA202402786B publication Critical patent/ZA202402786B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2024/02786A 2021-10-25 2024-04-10 Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis ZA202402786B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2021/079584 WO2023072368A1 (en) 2021-10-25 2021-10-25 Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis
PCT/EP2022/079666 WO2023072878A1 (en) 2021-10-25 2022-10-24 Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis

Publications (1)

Publication Number Publication Date
ZA202402786B true ZA202402786B (en) 2025-07-30

Family

ID=78536154

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/02786A ZA202402786B (en) 2021-10-25 2024-04-10 Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis

Country Status (11)

Country Link
US (1) US20250041228A1 (cg-RX-API-DMAC7.html)
EP (1) EP4312994A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024536609A (cg-RX-API-DMAC7.html)
KR (1) KR20240093898A (cg-RX-API-DMAC7.html)
CN (1) CN118234489A (cg-RX-API-DMAC7.html)
AU (1) AU2022374695A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230682A1 (cg-RX-API-DMAC7.html)
IL (1) IL312176A (cg-RX-API-DMAC7.html)
MX (1) MX2024005076A (cg-RX-API-DMAC7.html)
WO (2) WO2023072368A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202402786B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297020A (en) 2020-04-24 2022-12-01 Dr Falk Pharma Gmbh A systemic preparation of a pyridonone derivative related to tg2
HRP20231072T1 (hr) 2020-04-24 2023-12-22 Dr. Falk Pharma Gmbh Sustavna formulacija derivata piridinona za celijakiju
WO2025153465A1 (en) * 2024-01-15 2025-07-24 UCB Biopharma SRL Method for the treatment of fibrotic-related disorder associated to ibd

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006052755A1 (de) * 2006-11-08 2008-05-15 N-Zyme Biotec Gmbh Michaelsysteme als Transglutaminaseinhibitoren
EP2687511A1 (de) * 2012-07-17 2014-01-22 Zedira GmbH Pyridinonderivate als Gewebetransglutaminaseinhibitoren

Also Published As

Publication number Publication date
IL312176A (en) 2024-06-01
JP2024536609A (ja) 2024-10-04
KR20240093898A (ko) 2024-06-24
US20250041228A1 (en) 2025-02-06
WO2023072368A1 (en) 2023-05-04
WO2023072878A1 (en) 2023-05-04
CN118234489A (zh) 2024-06-21
EP4312994A1 (en) 2024-02-07
AU2022374695A1 (en) 2024-03-21
CA3230682A1 (en) 2023-05-04
MX2024005076A (es) 2024-05-13

Similar Documents

Publication Publication Date Title
KR102065193B1 (ko) 로수바스타틴 칼슘의 약학 조성물
MX2024005076A (es) Formulacion oral de un derivado de piridinona y su uso en la profilaxis y/o el tratamiento de la fibrosis intestinal.
CA2761947A1 (en) Coated pharmaceutical capsule dosage form
KR20130086128A (ko) 복용 용이성 고형 제제
TWI590835B (zh) 含有氫嗎啡酮(hydromorphone)和納洛酮(naloxone)之藥學組成物
US12622875B2 (en) Dosage form comprising an alkaline agent and an enteric coating layer
EP3445340A1 (en) Oral pharmaceutical compositions of mesalazine
US8299052B2 (en) Pharmaceutical compositions and methods for improved bacterial eradication
US11622938B2 (en) Oral pharmaceutical compositions of nicotinamide
CN105025883A (zh) 右哌甲酯或其盐的调节释放的药物组合物
CA3160869C (en) Dosage form for use in treating or preventing of a disease
JP2019513801A5 (cg-RX-API-DMAC7.html)
KR20210073285A (ko) 프로톤펌프억제제 및 모사프리드를 포함하는 유핵정 제제
JP2021503448A5 (cg-RX-API-DMAC7.html)
CN105640909B (zh) 一种含有达比加群酯的药用组合物
RS66154B1 (sr) Formulacije stimulansa sa tropulsnim oslobađanjem
WO2017111637A1 (en) Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
Derle Formulation Strategies for Controlled Drug Release Using MUPS Tablets: Advances and Challenges
JPWO2015045604A1 (ja) 口腔内崩壊錠
AU2006321782B2 (en) Pharmaceutical compositions and methods for improved bacterial eradication
CN110354125A (zh) 一种治疗幽门螺杆菌感染的组合物及其制剂和用途
JP2006327943A (ja) 経時的溶出遅延を抑制したテイストマスク錠剤
CN108472260B (zh) 用于制备包括富马酸二甲酯的肠溶包衣颗粒的方法
CZ27703U1 (cs) Kapsle obsahující Tamsulosin.HCI v peletách s prodlouženým uvolňováním
Salve Optimization of aqueous based film coating technique for pellets in colon specific delivery of mesalamine